Gibson Dunn Advises XOMA Royalty Corporation on Acquisition of HilleVax, Inc.
Firm News | August 13, 2025
Gibson Dunn is representing XOMA Royalty Corporation, a publicly traded biotech royalty aggregator, on its acquisition of HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company that was focused on developing and commercializing novel vaccines.
Gibson Dunn regularly advises life sciences companies and investors on complex mergers and acquisitions in the biotechnology sector.
The Gibson Dunn corporate team includes Ryan Murr, Branden Berns, and Chad Kang. Team members advising on additional aspects of the transaction include Pamela Lawrence Endreny (tax), Sean Feller and Spencer Bankhead (employee benefits), Jessica Valenzuela, Hazel Granada, and Minae Seog (litigation).